Session Information
Date: Monday, September 23, 2019
Session Title: Quality of Life
Session Time: 1:45pm-3:15pm
Location: Les Muses Terrace, Level 3
Objective: We aimed to compare the determinants of life quality between drug naïve PD and MSA-P patients.
Background: To improve the quality of life (QoL) has been termed as a main objective in imitating therapy in both Parkinson’s disease (PD) and multiple system atrophy-Parkinsonian subtype (MSA-P). However, the information on the QoL in drug-naïve PD and MSA-P patients is still limited.
Method: Eighty-six drug-naïve PD patients and thirty-six drug-naïve MSA-P patients were included to explore the determinants of QoL. Parkinson’s Disease Quality of Life Questionnaire (PDQ-39) was adopted to assess QoL. Demographic information, motor deficits, non-motor symptoms were included in the clinical assessment. Correlations between baseline clinical features and QoL were assessed using Spearman’s rho correlation coefficient. Linear regression model and multiple stepwise regressions were used to uncover the main determinants of the QoL. A two-year follow up was also conducted for further analysis.
Results: Both motor and non-motor functions were more severely injured in the drug-naïve MSA-P patients, with higher PDQ-39 scores and poorer QoL. Physical discomfort and stigma were the sub-domains mostly affected in PD, while mobility and ADL were mostly affected in MSA-P. A two-years follow-up verified a similar distribution pattern of PDQ-39. BECK depressive scores and UPDRS-III scores were the two independent variables of PDQ-39 in MSA-P patients. Age, depression, disease stages and non-motor scores were independent variables of PDQ-39 in PD patients.
Conclusion: Drug-naïve MSA-P patients suffered from more serious motor and non-motor disability, as well as poorer QoL. Depression and non-motor symptoms were proved to be the most critical factor of the PDQ-39 in PD, while motor function was supposed to be the major determinant for MSA-P. Physicians need to focus more on motor functions in drug-naïve MSA-P patients, but on depression in PD patients, when initiating therapy.
To cite this abstract in AMA style:
FT. Liu, J. Wang. Considerations before initiating therapy in Parkinsonism: basing on the health-related quality of life. [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/considerations-before-initiating-therapy-in-parkinsonism-basing-on-the-health-related-quality-of-life/. Accessed June 15, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/considerations-before-initiating-therapy-in-parkinsonism-basing-on-the-health-related-quality-of-life/